The FDA has approved the inclusion of new evidence showing that secukinumab (Cosentyx) significantly reduces the progression of joint structural damage among patients with active psoriatic arthritis (PsA). The data will be added the prescribing information of the biologic.
The updated is based on data from the phase 3 study, FUTURE 5, which included 996 participants with PsA. Patients who received secukinumab experienced significant reductions in progression of joint structural damage at week 24 compared with placebo.
FDA Expands Psoriasis Drug Indication
FDA Approves Label Update for Psoriasis Biologic
Secukinumab is approved to treat PsA, active ankylosking spondylitis, and moderate to severe plaque psoriasis.